NEOG
What one share of Neogen holds
In Vitro and In Vivo Diagnostic Substances
Neogen Corporation and its subsidiaries develop, manufacture and market a diverse line of products and services dedicated to food and animal safety.
Neogen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-08-31; the balance sheet is as of 2026-08-31.
| Sales | $4.06 |
|---|---|
| Profit | −$0.26 |
| Capex (buildings and equipment) | $0.16 |
| Free cash flow | $0.23 |
| Cash and investments | $0.79 |
| Debt | $3.55 |
| Book value | $9.56 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $3.50 | $0.43 | $0.14 | $0.45 | — | $4.63 |
| 2018 | $3.82 | $0.61 | $0.20 | $0.46 | — | $5.41 |
| 2019 | $3.95 | $0.57 | $0.14 | $0.47 | — | $6.11 |
| 2020 | $3.96 | $0.56 | $0.23 | $0.58 | — | $6.85 |
| 2021 | $4.37 | $0.57 | $0.25 | $0.51 | — | $7.82 |
| 2022 | $4.88 | $0.45 | $0.23 | $0.40 | — | $8.23 |
| 2023 | $4.35 | −$0.12 | $0.35 | −$0.13 | — | $14.49 |
| 2024 | $4.27 | −$0.04 | $0.51 | −$0.35 | — | $14.49 |
| 2025 | $4.12 | −$5.03 | $0.48 | −$0.21 | — | $9.54 |
| 2026 | $4.00 | −$0.04 | $0.24 | $0.15 | — | $9.61 |